Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2% – Here’s Why
by Kim Johansen · The Markets DailyBelite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) dropped 7.2% during mid-day trading on Thursday . The stock traded as low as $169.01 and last traded at $166.1130. 171,796 shares changed hands during mid-day trading, a decline of 11% from the average daily volume of 192,334 shares. The stock had previously closed at $178.94.
Belite Bio News Summary
Here are the key news stories impacting Belite Bio this week:
- Positive Sentiment: Quarterly loss was narrower than expected. Belite Bio reported second-quarter 2026 EPS of -$0.54, beating the analyst consensus of -$0.73 by $0.19. The earnings surprise may support the stock by suggesting better-than-expected cost control or operating performance. Belite Bio quarterly earnings results
- Positive Sentiment: HC Wainwright sees substantial upside potential. The research firm issued a bullish forecast for BLTE, which could improve investor sentiment toward Belite Bio’s pipeline and long-term prospects. The report’s headline did not provide a specific price target in the available information. HC Wainwright forecast for Belite Bio
- Neutral Sentiment: Management provided a second-quarter financial and corporate update. Belite Bio released unaudited results for the quarter ended June 30, 2026, and discussed its business as it advances therapies for degenerative retinal diseases. Investors will likely focus on pipeline milestones, regulatory progress and cash resources from the update. Belite Bio second-quarter 2026 results and corporate update
- Negative Sentiment: CEO and CFO both sold small portions of their holdings. CEO Yu-Hsin Lin sold 365 shares and CFO Hao-Yuan Chuang sold 367 shares at an average price of $180.35. The transactions reduced their direct holdings by only 0.21% and 0.39%, respectively, limiting the significance, but simultaneous executive sales can still create a modest negative sentiment signal. Belite Bio CEO insider sale filing
Analyst Ratings Changes
Several brokerages have commented on BLTE. Truist Financial set a $217.00 target price on Belite Bio in a research note on Friday, May 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Belite Bio in a report on Monday, July 6th. Mizuho set a $220.00 target price on shares of Belite Bio in a research report on Friday. Cantor Fitzgerald increased their price target on Belite Bio from $266.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Zacks Research raised Belite Bio from a “hold” rating to a “strong-buy” rating in a report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $205.80.
Check Out Our Latest Analysis on BLTE
Belite Bio Price Performance
The company has a 50-day moving average price of $152.50 and a 200 day moving average price of $159.86. The firm has a market capitalization of $6.53 billion, a PE ratio of -59.63 and a beta of -1.22.
Belite Bio (NASDAQ:BLTE – Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.54) earnings per share (EPS) for the quarter. As a group, research analysts anticipate that Belite Bio, Inc. Sponsored ADR will post -3.17 earnings per share for the current year.
Insider Buying and Selling
In other news, CEO Yu-Hsin Lin sold 365 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $180.35, for a total transaction of $65,827.75. Following the transaction, the chief executive officer owned 170,569 shares of the company’s stock, valued at approximately $30,762,119.15. The trade was a 0.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Hendrik Peter Scholl sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $145.24, for a total transaction of $1,452,400.00. Following the completion of the sale, the insider owned 15,000 shares of the company’s stock, valued at $2,178,600. This trade represents a 40.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 20,732 shares of company stock worth $2,990,116. Insiders own 13.29% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Darwin Global Management Ltd. purchased a new stake in shares of Belite Bio in the fourth quarter valued at approximately $486,915,000. RA Capital Management L.P. purchased a new position in Belite Bio during the third quarter valued at approximately $64,750,000. Millennium Management LLC boosted its position in Belite Bio by 2,594.6% during the 4th quarter. Millennium Management LLC now owns 558,882 shares of the company’s stock valued at $89,399,000 after acquiring an additional 538,141 shares in the last quarter. RTW Investments LP raised its position in shares of Belite Bio by 128.9% in the 4th quarter. RTW Investments LP now owns 715,332 shares of the company’s stock worth $114,425,000 after acquiring an additional 402,832 shares in the last quarter. Finally, Perceptive Advisors LLC grew its stake in Belite Bio by 732.0% in the fourth quarter. Perceptive Advisors LLC now owns 414,239 shares of the company’s stock valued at $66,262,000 after purchasing an additional 364,451 shares during the last quarter. 0.53% of the stock is currently owned by institutional investors.
Belite Bio Company Profile
Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.
Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.